KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Common Equity: 2020-2025

Historic Common Equity for Recursion Pharmaceuticals (RXRX) over the last 5 years, with Sep 2025 value amounting to $1.0 billion.

  • Recursion Pharmaceuticals' Common Equity rose 99.59% to $1.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 billion, marking a year-over-year increase of 99.59%. This contributed to the annual value of $1.0 billion for FY2024, which is 123.28% up from last year.
  • Recursion Pharmaceuticals' Common Equity amounted to $1.0 billion in Q3 2025, which was up 13.90% from $919.1 million recorded in Q2 2025.
  • In the past 5 years, Recursion Pharmaceuticals' Common Equity registered a high of $1.0 billion during Q3 2025, and its lowest value of -$233.0 million during Q1 2021.
  • For the 3-year period, Recursion Pharmaceuticals' Common Equity averaged around $658.7 million, with its median value being $524.6 million (2024).
  • In the last 5 years, Recursion Pharmaceuticals' Common Equity spiked by 363.19% in 2021 and then tumbled by 35.22% in 2022.
  • Recursion Pharmaceuticals' Common Equity (Quarterly) stood at $542.9 million in 2021, then fell by 10.52% to $485.8 million in 2022, then fell by 4.60% to $463.4 million in 2023, then soared by 123.28% to $1.0 billion in 2024, then surged by 99.59% to $1.0 billion in 2025.
  • Its Common Equity stands at $1.0 billion for Q3 2025, versus $919.1 million for Q2 2025 and $933.9 million for Q1 2025.